Treatmentexperimental

Cancer Early-Detection Blood Test (MCED)

A multi-cancer early-detection blood test (e.g.

A multi-cancer early-detection blood test (e.g. Galleri) that screens for circulating tumor-DNA signals across many cancer types, offered as an add-on to premium longevity and executive-health assessments.

Evidence

experimental

MCED tests are promising but not yet proven to reduce cancer mortality; sensitivity for early-stage cancers is limited and randomized outcome trials are still ongoing, so the screening/longevity claim is unproven.

Regulatory notes

European Union
Sold as laboratory-developed/wellness tests; not approved by EMA as validated screening tools and not part of any EU screening program.
United States
Available as an LDT (e.g. Galleri) but has NOT received full FDA approval as a screening test, with outcome trials pending.
United Arab Emirates
Offered within DHA/DoH-licensed clinics as a self-pay adjunct; not an approved population-screening tool.
United Kingdom
Being trialed by the NHS but not approved for routine screening; sold privately as an add-on.

General information, not medical or legal advice. See our disclaimer.

Also known as

multi-cancer early detection, MCED test, Galleri, liquid biopsy screening, circulating tumor DNA test, ctDNA screening, early cancer detection blood test

Where to find it

88 clinics in the directory offer cancer early-detection blood test (mced). Prices shown are the cheapest for this treatment where published; always confirm with the venue.

London

Back to glossary